Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Procter & Gamble HealthBOM:500126 -0.21%78 Return-on-Tangible-Asset is 45.74% as of Jun. 2026, which is 142% above its 10-year median of 18.89. GuruFocus rates BOM:500126 with a GF Score™ of 78/100 and a GF Value™ of ₹5,695.85 (Fairly Valued). The stock has 2 warning signs investors should review. Among 1,008 Drug Manufacturers companies, Procter & Gamble Health ranks better than 98.61% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Procter & Gamble Health's annualizedNet Income for the quarter that ended in Jun. 2026 was ₹3,846 Mil. Procter & Gamble Health's average total tangible assets for the quarter that ended in Jun. 2026 was ₹8,409 Mil. Therefore, Procter & Gamble Health's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2026 was 45.74%.
The historical rank and industry rank for Procter & Gamble Health's Return-on-Tangible-Asset or its related term are showing as below:
BOM:500126'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 7.21 Med: 18.89 Max: 61.01
Current: 42.35
During the past 13 years, Procter & Gamble Health's highest Return-on-Tangible-Asset was 61.01%. The lowest was 7.21%. And the median was 18.89%.
BOM:500126's Return-on-Tangible-Asset is ranked better than 98.61% of 1008
companies
in the Drug Manufacturers industry
Industry Median: 2.795
vs BOM:500126: 42.35
Procter & Gamble Health (BOM:500126) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Procter & Gamble Health Return-on-Tangible-Asset Related Terms
Procter & Gamble Health Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Procter & Gamble Health's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Procter & Gamble Health Return-on-Tangible-Asset Chart
BOM:500126 vs ZTS: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Procter & Gamble Health's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Procter & Gamble Health Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Procter & Gamble Health's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Procter & Gamble Health's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of 45.74% mean?
Procter & Gamble Health (BOM:500126) has a Return-on-Tangible-Asset of 45.74% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Procter & Gamble Health and its competitors. This is 142% above median its historical median of 18.89. Over the past decade, Procter & Gamble Health's Return-on-Tangible-Asset has ranged from 7.21 to 61.01. According to the industry distribution chart, Procter & Gamble Health ranks #14 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 1.4%.
Is Procter & Gamble Health's Return-on-Tangible-Asset too high?
Procter & Gamble Health's current Return-on-Tangible-Asset of 45.74% is 142% above median its 10-year median of 18.89. Over the past 10 years, this metric has ranged from a low of 7.21 to a high of 61.01. The Drug Manufacturers industry median Return-on-Tangible-Asset is 2.80. Procter & Gamble Health's value of 45.74% is 1536.5% above this industry median. Based on the distribution chart, Procter & Gamble Health ranks #14 out of 1008 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Procter & Gamble Health has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Procter & Gamble Health's Return-on-Tangible-Asset compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Procter & Gamble Health ranks #14 out of 1008 companies for Return-on-Tangible-Asset. This places Procter & Gamble Health in the top 1% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 2.80. Procter & Gamble Health's value of 45.74% is 1536.5% above this benchmark. Historically, Procter & Gamble Health's own Return-on-Tangible-Asset has ranged from 7.21 to 61.01 over the past decade. While the company's 10-year median is 18.89 vs. the industry median of 2.80, Procter & Gamble Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 2.80, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Procter & Gamble Health's current Return-on-Tangible-Asset of 45.74% is 1536.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Procter & Gamble Health and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Procter & Gamble Health's current Return-on-Tangible-Asset is 45.74%, which is 142% above median its own 10-year median of 18.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Procter & Gamble Health stock overvalued right now?
Based on GuruFocus' analysis, Procter & Gamble Health (BOM:500126) is currently considered Fairly Valued. The stock's GF Value™ is ₹5,695.85, compared to a current price of ₹5,410.15 — trading 5% below its estimated fair value. The current Return-on-Tangible-Asset is 45.74%, which is 142% above median its 10-year median of 18.89 and 1536.5% above the Drug Manufacturers industry median of 2.80. Procter & Gamble Health's overall GF Score™ is 78/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Procter & Gamble Health (BOM:500126), the current Return-on-Tangible-Asset is 45.74% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Procter & Gamble Health (BOM:500126) Overvalued in 2026?
Based on GuruFocus' analysis, Procter & Gamble Health stock appears to be undervalued.
The current stock price of ₹5,410.15 is trading 5% below its estimated GF Value™ of ₹5,695.85.
GuruFocus considers Procter & Gamble Health to be Fairly Valued.
Key valuation signals for BOM:500126:
Return-on-Tangible-Asset: 45.74% (142% above median its 10-year median of 18.89)
GF Value™: ₹5,695.85 vs. price of ₹5,410.15 (5% below fair value)
Industry Position: 1536.5% above the Drug Manufacturers median (#14 of 1008)
No single metric tells the full story. See the BOM:500126 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Procter & Gamble Health Ltd is an India based pharmaceutical company engaged in manufacturing and selling of healthcare products, viz., vitamins, minerals and supplements. Patients are end consumers of the products. The Company's distribution channels (direct & indirect), inter alia, include distributors, health care professionals, pharmacies and chemists. Cosome, Evion, Neurobion, Nasivion, Polybion, Livogen and Seven Seas are some of the brands of the company. The geographical segments include sales in India and exports.
78GF Score
Get the complete analysis for BOM:500126
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:500126 has been successfully added to your 
